Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- EGFR Gene Mutation
- Lung Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
This is a prospective, multi-center, single-arm clinical trial to evaluate the safety and effectiveness of Almonertinib treatment in patients with EGFR mutation positive and advanced non-small cell lung cancer (NSCLC) who are intolerant to the safety of osimertinib treatment. Patients meeting the cr...
This is a prospective, multi-center, single-arm clinical trial to evaluate the safety and effectiveness of Almonertinib treatment in patients with EGFR mutation positive and advanced non-small cell lung cancer (NSCLC) who are intolerant to the safety of osimertinib treatment. Patients meeting the criteria for inclusion and exclusion were included in the Almonertinib treatment group and received 110 mg of Almonertinib orally once a day.
Tracking Information
- NCT #
- NCT04882345
- Collaborators
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Investigators
- Principal Investigator: Yongsheng Li The Affiliated Cancer Hospital of Chongqing University Principal Investigator: Jianying Zhou First Affiliated Hospital of Zhejiang University School of Medicine Principal Investigator: Xiuyu Cai Sun Yat-sen University Principal Investigator: Yueyin Pan The First Affiliated Hospital of University of Science and Technology of China Principal Investigator: Wenxiu Yao Sichuan Cancer Hospital and Research Institute Principal Investigator: Chun Huang Tianjin Cancer Hospital Principal Investigator: Minglei Zhuo Beijing Cancer Hospital Principal Investigator: Conghua Xie Wuhan University Principal Investigator: Meiqi Shi Jiangsu Cancer Institute & Hospital Principal Investigator: Qibin Song Hubei Provincial People's Hospital
Get Well Soon